Shereen Z. Ezzat
#146,447
Most Influential Person Now
Shereen Z. Ezzat's AcademicInfluence.com Rankings
Shereen Z. Ezzatphilosophy Degrees
Philosophy
#7903
World Rank
#11184
Historical Rank
Logic
#4938
World Rank
#6277
Historical Rank
Download Badge
Philosophy
Why Is Shereen Z. Ezzat Influential?
(Suggest an Edit or Addition)Shereen Z. Ezzat's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The prevalence of pituitary adenomas (2004) (890)
- Pathogenetic mechanisms in thyroid follicular-cell neoplasia (2006) (867)
- The pathogenesis of pituitary tumours (2002) (386)
- The cytogenesis and pathogenesis of pituitary adenomas. (1998) (381)
- Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. (1995) (367)
- Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma (2001) (329)
- Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. (2009) (310)
- Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. (1998) (306)
- Insulin and related factors in premenopausal breast cancer risk (2004) (279)
- Octreotide treatment of acromegaly. A randomized, multicenter study. (1992) (270)
- Cystic lesions of the pituitary: clinicopathological features distinguishing craniopharyngioma, Rathke's cleft cyst, and arachnoid cyst. (1999) (247)
- American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. (2011) (236)
- Mutations of the MEN1 tumor suppressor gene in pituitary tumors. (1997) (235)
- From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. (2017) (223)
- Acromegaly: Clinical and Biochemical Features in 500 Patients (1994) (218)
- Diagnosis and management of hyperprolactinemia. (2003) (218)
- The spectrum and significance of primary hypophysitis. (2001) (186)
- Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. (2002) (184)
- Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. (2001) (184)
- The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. (2006) (182)
- Women awaiting knee replacement have reduced function and growth hormone. (2003) (162)
- The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. (2005) (159)
- Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. (2009) (151)
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND TREATMENT OF ACROMEGALY (2004) (149)
- Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. (2002) (149)
- A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors (2008) (143)
- The pathogenesis of pituitary tumors. (2009) (141)
- Biomarkers of aggressive pituitary adenomas. (2012) (137)
- Molecular basis of Hurthle cell papillary thyroid carcinoma (2000) (136)
- A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors (2018) (133)
- Myostatin is a skeletal muscle target of growth hormone anabolic action. (2003) (133)
- The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. (1996) (132)
- Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. (2007) (131)
- Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. (1994) (130)
- Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. (1996) (129)
- The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. (2008) (129)
- Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. (2005) (125)
- Acromegaly: Re-thinking the cancer risk (2008) (121)
- A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly (2009) (121)
- Altered expression of fibroblast growth factor receptors in human pituitary adenomas. (1997) (118)
- ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? (1996) (112)
- Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-deficient adults. (1999) (105)
- Clonality of thyroid nodules in sporadic goiter. (1995) (105)
- Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. (2012) (103)
- Prevalence of activating ras mutations in morphologically characterized thyroid nodules. (1996) (103)
- The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations (2018) (102)
- Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas (2016) (101)
- Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. (2002) (98)
- Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. (1995) (96)
- Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. (2009) (92)
- Oncogene profile of papillary thyroid carcinoma. (1999) (90)
- Mechanisms of Disease: the pathogenesis of pituitary tumors (2006) (90)
- Improved diagnostic accuracy of inferior petrosal sinus sampling over imaging for localizing pituitary pathology in patients with Cushing's disease. (1998) (88)
- Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. (2005) (88)
- Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms (2022) (87)
- Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. (2004) (86)
- Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. (1995) (84)
- Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. (2018) (84)
- Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5' fibroblast growth factor receptor-4 promoter. (2003) (82)
- Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. (2002) (82)
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly--2011 update: executive summary. (2011) (81)
- Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. (2016) (81)
- A High-Throughput Proteomic Approach Provides Distinct Signatures for Thyroid Cancer Behavior (2011) (79)
- Somatotroph hyperplasia without pituitary adenoma associated with a long standing growth hormone-releasing hormone-producing bronchial carcinoid. (1994) (79)
- Controversies in papillary microcarcinoma of the thyroid (2003) (75)
- The MEN-1 gene is rarely down-regulated in pituitary adenomas. (1998) (73)
- Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. (2007) (72)
- Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review. (2010) (71)
- Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. (2004) (70)
- The Impact of Thyroid Cancer and Post-Surgical Radioactive Iodine Treatment on the Lives of Thyroid Cancer Survivors: A Qualitative Study (2009) (67)
- Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature (2012) (67)
- Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. (2007) (67)
- A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors (2008) (67)
- Cancer-related worry in Canadian thyroid cancer survivors. (2015) (67)
- Fibroblast Growth Factor 2 and Estrogen Control the Balance of Histone 3 Modifications Targeting MAGE-A3 in Pituitary Neoplasia (2008) (65)
- Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice. (2000) (65)
- Basic fibroblast growth factor expression by two prolactin and thyrotropin-producing pituitary adenomas (1995) (65)
- CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases (2007) (64)
- The Role of Hormones, Growth Factors and Their Receptors in Pituitary Tumorigenesis (2001) (63)
- IGF‐I and testosterone levels as predictors of bone mineral density in healthy, community‐dwelling men (2004) (61)
- Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. (2004) (61)
- A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial (2019) (61)
- A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. (2007) (61)
- The FGFR4-G388R Polymorphism Promotes Mitochondrial STAT3 Serine Phosphorylation to Facilitate Pituitary Growth Hormone Cell Tumorigenesis (2011) (61)
- The endogenous fibroblast growth factor-2 antisense gene product regulates pituitary cell growth and hormone production. (2001) (59)
- Membrane-anchored expression of transforming growth factor-alpha in human pituitary adenoma cells. (1995) (59)
- A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. (2007) (59)
- The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. (2014) (58)
- Ikaros integrates endocrine and immune system development. (2005) (57)
- AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. (2004) (56)
- Carney complex with adrenal cortical carcinoma. (2012) (56)
- Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. (2008) (55)
- Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas. (2014) (54)
- The Cancer/Testis Antigen Melanoma-Associated Antigen-A3/A6 Is a Novel Target of Fibroblast Growth Factor Receptor 2-IIIb through Histone H3 Modifications in Thyroid Cancer (2007) (53)
- The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. (2012) (53)
- Overt immune dysfunction after Cushing's syndrome remission: a consecutive case series and review of the literature. (2011) (49)
- Tumor-derived Ikaros 6 acetylates the Bcl-XL promoter to up-regulate a survival signal in pituitary cells. (2006) (49)
- 1alpha,25-Dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness. (2005) (49)
- Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms. (2002) (48)
- Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines. (2019) (48)
- Treatment Options for Pancreatic Neuroendocrine Tumors (2019) (47)
- Molecular Determinants of Pituitary Cytodifferentiation (1999) (47)
- Psychological Features of Acromegaly (1998) (46)
- The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility. (2005) (46)
- Pancreatic endocrine pathology in von hippel-lindau disease: An expanding spectrum of lesions (2004) (46)
- Molecular basis of pituitary development and cytogenesis. (2004) (45)
- A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer. (2018) (44)
- An essential role for the hematopoietic transcription factor Ikaros in hypothalamic–pituitary-mediated somatic growth (2006) (42)
- Distinct clonal composition of primary and metastatic adrencorticotrophic hormone‐producing pituitary carcinoma (2001) (41)
- Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. (2007) (41)
- Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications. (2006) (41)
- Pituitary Tumor AP-2α Recognizes a Cryptic Promoter in Intron 4 of Fibroblast Growth Factor Receptor 4* (2003) (41)
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: CLINICAL RELEVANCE OF MACROPROLACTIN IN THE ABSENCE OR PRESENCE OF TRUE HYPERPROLACTINEMIA. (2015) (39)
- The c‐erbB‐2/neu proto‐oncogene in human pituitary tumours (1997) (39)
- Cushing’s Syndrome from an ectopic pituitary adenoma with peliosis: A histological, immunohistochemical, and ultrastructural study and review of the literature (1997) (39)
- Fibroblast growth factor receptor 4 is a target for the zinc-finger transcription factor Ikaros in the pituitary. (2002) (39)
- Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association (2015) (39)
- Genetics and proteomics of pituitary tumors (2005) (39)
- Aggressive Pituitary Tumors or Localized Pituitary Carcinomas: Defining Pituitary Tumors (2016) (38)
- Growth patterns of pituitary adenomas and histopathological correlates. (2014) (38)
- Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells. (2008) (37)
- Patients' experiences following local–regional recurrence of thyroid cancer: A qualitative study (2013) (36)
- Cancer family history characterization in an unselected cohort of 121 patients with uveal melanoma (2010) (36)
- Epigenetic dysregulation in thyroid neoplasia. (2008) (36)
- Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior (2013) (35)
- Emerging trends in the diagnosis and treatment of acromegaly in Canada (2013) (35)
- A soluble dominant negative fibroblast growth factor receptor 4 isoform in human MCF-7 breast cancer cells. (2001) (35)
- Vitamin D and Its Analog EB1089 Induce p27 Accumulation and Diminish Association of p27 with Skp2 Independent of PTEN in Pituitary Corticotroph Cells (2002) (35)
- Canadian consensus guidelines for the diagnosis and management of acromegaly. (2006) (34)
- A Prospective Mixed-Methods Study of Decision-Making on Surgery or Active Surveillance for Low-Risk Papillary Thyroid Cancer (2020) (33)
- The Role of Mediators of Cell Invasiveness, Motility, and Migration in the Pathogenesis of Silent Corticotroph Adenomas (2013) (33)
- Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. (2009) (32)
- An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors (2019) (32)
- Exercise training benefits growth hormone (GH)-deficient adults in the absence or presence of GH treatment. (2003) (31)
- Epigenetic control in pituitary tumors. (2008) (31)
- Molecular basis off hurthle cell papillary thyroid carcinoma. (2000) (31)
- Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting. (2005) (31)
- Protocol for the examination of specimens from patients with primary pituitary tumors. (2011) (31)
- The Clinicopathological Spectrum of Acromegaly (2019) (31)
- Cytoplasmic staining of erbB‐2 but not mRNA levels correlates with differentiation in human thyroid neoplasia (1998) (30)
- PREDICTIVE MARKERS FOR POSTSURGICAL MEDICAL MANAGEMENT OF ACROMEGALY: A SYSTEMATIC REVIEW AND CONSENSUS TREATMENT GUIDELINE. (2019) (30)
- Evaluation of the WHO 2010 Grading and AJCC/UICC Staging Systems in Prognostic Behavior of Intestinal Neuroendocrine Tumors (2013) (28)
- The Breast Cancer Susceptibility Gene Product Fibroblast Growth Factor Receptor 2 Serves as a Scaffold for Regulation of NF-κB Signaling (2012) (28)
- Longitudinal assessment of economic burden and clinical outcomes in acromegaly. (2001) (28)
- Growth hormone‐releasing hormone (GHRH) and GHRH receptor (GHRH‐R) isoform expression in ectopic acromegaly (2001) (28)
- Case Report: Adrenal LH/hCG Receptor Overexpression and Gene Amplification Causing Pregnancy-Induced Cushing’s Syndrome (2009) (28)
- Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution (2019) (27)
- Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor (1993) (27)
- AIP Mutations are not Identified in Patients with Sporadic Pituitary Adenomas (2007) (27)
- Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors (2020) (27)
- FGF receptor signaling at the crossroads of endocrine homeostasis and tumorigenesis. (2005) (27)
- Osteopontin (OPN) expression in thyroid carcinoma. (2010) (27)
- Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification (2021) (26)
- Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of von Hippel–Lindau disease (2013) (26)
- Pituitary acromegaly: not one disease. (2017) (26)
- FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression. (2012) (26)
- Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician. (2015) (26)
- Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess (2002) (25)
- Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications (2017) (25)
- Ikaros is regulated through multiple histone modifications and deoxyribonucleic acid methylation in the pituitary. (2007) (25)
- Ikaros modulates cholesterol uptake: a link between tumor suppression and differentiation. (2008) (24)
- Persistent posttreatment fatigue in thyroid cancer survivors: a scoping review. (2014) (24)
- Pituitary Adenomas Presenting as Sinonasal or Nasopharyngeal Masses: A Case Series Illustrating Potential Diagnostic Pitfalls (2017) (24)
- Expression of steroidogenic factor-1 (SF-1) mRNA and protein in the human placenta. (1996) (23)
- Hypothalamic Vasopressin-Producing Tumors: Often Inappropriate Diuresis But Occasionally Cushing Disease (2019) (23)
- The epigenetic landscape of differentiated thyroid cancer (2017) (23)
- The Clinicopathological Spectrum of Parathyroid Carcinoma (2019) (23)
- A primer on the genetics of medullary thyroid cancer. (2019) (22)
- Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages (2018) (22)
- CtBP1 interacts with Ikaros and modulates pituitary tumor cell survival and response to hypoxia. (2012) (22)
- The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes. (2013) (22)
- The Role of Diabetes in Acromegaly Associated Neoplasia (2015) (22)
- Basis for physician recommendations for adjuvant radioiodine therapy in early-stage thyroid carcinoma: principal findings of the Canadian-American thyroid cancer survey. (2008) (21)
- The emerging role of the Ikaros stem cell factor in the neuroendocrine system. (2008) (21)
- A Systematic Review and Meta-Analysis of the Diagnostic Performance of BRAF V600E Immunohistochemistry in Thyroid Histopathology (2019) (21)
- Chromatin remodeling and histone modifications in pituitary tumors (2010) (21)
- Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States. (2007) (20)
- A prospective multicenter octreotide dose response study in the treatment of acromegaly (1995) (20)
- Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer. (2010) (19)
- Circulating and synovial levels of IGF‐I, cytokines, physical function and anthropometry differ in women awaiting total knee arthroplasty when compared to men (2005) (19)
- Management of Small Bowel Neuroendocrine Tumors (2019) (19)
- Management of Lesions of the Pituitary Stalk and Hypothalamus (2003) (19)
- Sp1-Mediated Transcriptional Control of Fibroblast Growth Factor Receptor 4 in Sarcomas of Skeletal Muscle Lineage (2004) (19)
- The Cost of Medical Care for the Acromegalic Patient (2006) (19)
- Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer. (2009) (19)
- Intrathyroidal Parathyroid Carcinoma: An Atypical Thyroid Lesion (2018) (18)
- How can we meet the information needs of patients with early stage papillary thyroid cancer considering radioactive iodine remnant ablation? (2011) (18)
- FGFR4 polymorphic variants modulate phenotypic features of Cushing disease. (2014) (17)
- Thyroid cancer patients’ involvement in adjuvant radioactive iodine treatment decision-making and decision regret: an exploratory study (2011) (17)
- Current management of papillary thyroid microcarcinoma in Canada (2014) (17)
- The Insulin Resistance Grb14 Adaptor Protein Promotes Thyroid Cancer Ret Signaling and Progression (2011) (16)
- Functional Cardiac Paraganglioma Associated with a Rare SDHC Mutation (2014) (16)
- High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor (2016) (16)
- Unmet Information Needs of Low-Risk Thyroid Cancer Survivors. (2016) (16)
- Malignant pheochromocytoma secreting vasoactive intestinal peptide and response to sunitinib: a case report and literature review. (2014) (16)
- Medical Management of Pituitary Adenomas: Structural and Ultrastructural Changes (2004) (15)
- Vitamin D inhibits CEACAM1 to promote insulin/IGF-I receptor signaling without compromising anti-proliferative action (2011) (15)
- Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial (2015) (15)
- Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial. (2004) (15)
- Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer - a randomized controlled trial (2010) (15)
- Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease (2019) (14)
- Distinct transcriptional control and action of fibroblast growth factor receptor 4 in differentiating skeletal muscle cells (2004) (14)
- Metabolic Glucose Status and Pituitary Pathology Portend Therapeutic Outcomes in Acromegaly (2013) (14)
- A Systematic Review and Meta-Analysis of Patient Preferences for Combination Thyroid Hormone Treatment for Hypothyroidism (2019) (14)
- Mice lacking the transcription factor Ikaros display behavioral alterations of an anti-depressive phenotype (2008) (14)
- A detailed spatial analysis on contrasting cancer incidence patterns in thyroid and lung cancer in Toronto women (2016) (14)
- Osteopontin stimulates invasion of NCI‐h295 cells but is not associated with survival in adrenocortical carcinoma (2009) (14)
- Tyrosine kinase receptors as molecular targets In pheochromocytomas and paragangliomas (2014) (14)
- Continuous Versus Intermittent Subcutaneous Infusion of Octreotide in the Treatment of Acromegaly (1995) (14)
- Dexamethasone increases ubiquitin transcription through an SP-1 dependent mechanism in multiple myeloma cells. (2008) (13)
- Establishment and Characterization of a Human Neuroendocrine Tumor Xenograft (2016) (13)
- Pituitary Disorders: Diagnosis and Management (2013) (12)
- The breast cancer susceptibility FGFR2 provides an alternate mode of HER2 activation. (2015) (12)
- Autoimmune Hypophysitis (1997) (12)
- Co‐occurrence of breast cancer and neuroendocrine tumours: New genetic insights beyond Multiple Endocrine Neoplasia syndromes (2019) (12)
- Comprehensive characterization of a Canadian cohort of von Hippel‐Lindau disease patients (2019) (12)
- Brain metastasis from medullary thyroid carcinoma (2010) (11)
- A systematic review of randomized controlled trials for management of persistent post-treatment fatigue in thyroid cancer survivors. (2015) (11)
- FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors (2016) (11)
- AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease. (2014) (11)
- An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism (2021) (11)
- The molecular pathogenetic role of cell adhesion in endocrine neoplasia (2005) (11)
- The rationale of patients with early-stage papillary thyroid cancer for accepting or rejecting radioactive iodine remnant ablation. (2013) (10)
- Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know? (2021) (10)
- Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer. (2010) (10)
- Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter. (2002) (10)
- Is granulomatous thyroiditis a complication of breast implants? (2002) (10)
- Guidelines for the diagnosis and treatment of acromegaly: a Canadian perspective. (2000) (10)
- Dopaminergic Resistant Prolactinomas in the Peripubertal Population (2006) (9)
- Complex Endocrinopathies in MEN-1: Diagnostic Dilemmas in Endocrine Oncology (2007) (9)
- Genomic Approaches to Problems in Pituitary Neoplasia (2014) (9)
- Asynchronous pituitary adenomas with differing morphology. (1995) (9)
- Adjuvant Growth Hormone for Ovulation Induction with Gonadotropins in the Treatment of a Woman with Hypopituitarism (2012) (9)
- Fibroblast Growth Factor 2 and Estrogen Control the Balance of Histone 3 Modifications TargetingMAGE-A 3 in Pituitary Neoplasia (2008) (9)
- Concerns of low-risk thyroid cancer survivors (2016) (9)
- Microadenomatosis of the pancreas in von Hippel-Lindau disease. (2006) (9)
- Male occult triple-negative breast cancer with dermatomyositis: a case report and review of the literature (2017) (9)
- Pseudopheochromocytoma of pregnancy. (2003) (9)
- The diagnosis and management of acromegaly: a Canadian consensus report. (1996) (9)
- Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis (2019) (9)
- Genetic events in the evolution of thyroid cancer. (2002) (8)
- Comparison of body composition assessment methods in patients with human immunodeficiency virus-associated wasting receiving growth hormone. (2006) (8)
- Pancreatic Neuroendocrine Tumors Producing GHRH, GH, Ghrelin, PTH, or PTHrP (2015) (8)
- Exploring the relationship between patients’ information preference style and knowledge acquisition process in a computerized patient decision aid randomized controlled trial (2015) (8)
- Metastasis of urothelial sarcomatoid carcinoma to a toxic multinodular goiter (2005) (8)
- Pancreatic Neuroendocrine Tumor Producing Insulin and Vasopressin (2018) (8)
- A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly. (2009) (7)
- Pituitary tumor pathogenesis--the hunt for novel candidate genes continues. (2003) (7)
- NG2 targets tumorigenic Rb inactivation in Pit1-lineage pituitary cells. (2016) (7)
- The Pangenomic Classification of Pituitary Neuroendocrine Tumors: Quality Histopathology is Required for Accurate Translational Research (2021) (7)
- Progression of subacute (de Quervain's) thyroiditis into Hashimoto's thyroiditis. (2004) (7)
- Primary mediastinal paraganglioma associated with a familial variant in the succinate dehydrogenase B subunit gene (2018) (7)
- Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer: update to study protocol with follow-up extension (2015) (7)
- A large and aggressive fibromatosis in the axilla: a rare case report and review of the literature (2018) (6)
- Metastatic thyroid carcinoma to the gastric body. (2014) (6)
- Complete anterior pituitary failure and postpartum cardiomyopathy. (2006) (6)
- Clinical predictors of advanced sellar masses. (2007) (6)
- Endoscopic Endonasal Pituitary Surgery For Nonfunctioning Pituitary Adenomas: Long-Term Outcomes and Management of Recurrent Tumors. (2020) (6)
- The obesity epidemic. (2012) (5)
- Managing newly diagnosed thyroid cancer (2014) (5)
- Exploring the Life Impact of Treated Low-Risk Thyroid Cancer. (2016) (5)
- Gonadotrope Tumors. (2016) (5)
- Pathology, pathophysiology, and treatment strategies of endocrine disorders and their cardiac complications. (2013) (4)
- Symptom burden in adults with thyroid cancer (2018) (4)
- Significance of Crooke's Hyaline Change in Nontumorous Corticotrophs of Patients With Cushing Disease (2021) (4)
- A Mixed Methods Evaluation of a Computerized Decision Aid for Patients Considering Radioactive Iodine RemnantAblation: developing person-centered medicine for thyroid cancer (2011) (4)
- Ikaros and its interacting partner CtBP target the metalloprotease ADAMTS10 to modulate pituitary cell function (2017) (4)
- Canadian guidelines for the management of adult growth hormone deficiency. (2006) (4)
- Pharmacological approach to the treatment of acromegaly. (2004) (4)
- GNAq Mutations are Not Identified in Papillary Thyroid Carcinomas and Hyperfunctioning Thyroid Nodules (2010) (4)
- Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer. (2021) (4)
- Granulomatous hypophysitis with psammoma bodies: A diagnostic dilemma (2004) (4)
- Fibroblast growth factor receptor 4 ( FGFR 4 ) mediates signaling to the prolactin but not the FGFR 4 promoter (2002) (3)
- The retrotransposon gag domain containing protein Rgag4 is an Ikaros target in the pituitary (2017) (3)
- [13C]NMR studies of the effect of the somatostatin analogue octreotide on hepatic glycogenesis and glycogenolysis (1994) (3)
- Ultrasound in active surveillance for low-risk papillary thyroid cancer: imaging considerations in case selection and disease surveillance (2021) (3)
- Thyroid cancer is the most common malignancy arising from hormone-producing glands. Preface. (2008) (2)
- Current views on pathogenesis of pituitary tumors (2004) (2)
- Endoscopic treatment of sellar arachnoid cysts via a simple cyst-opening technique: Long-term outcomes from a single center. (2022) (2)
- Tools for Enhancement and Quality Improvement of Peer Assessment and Clinical Care in Endocrinology and Metabolism. (2017) (2)
- DNA Methyl-Transferase 3B Promotes Epigenetic Silencing Through Histone 3 Chromatin Modifications in Pituitary Cells (2008) (2)
- MALIGNANT OVARIAN STEROID CELL TUMOR CAUSING SEVERE HYPERANDROGENISM: CASE REPORT AND REVIEW OF THE LITERATURE (2017) (2)
- The Endocrine System (2013) (2)
- AACE / ACE Disease State Clinical Review (2015) (2)
- The Endocrine System (2013) (2)
- Retraction. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. (2015) (2)
- Temporal Trends in Thyroid Cancer Incidence in California—Letter (2014) (2)
- Spuriously Elevated Serum IGF-1 in Adult Individuals with Delayed Puberty: A Diagnostic Pitfall (2010) (2)
- Clinicopathological variations in cushing’s syndrome (1999) (2)
- The Cancer/Testis AntigenMelanoma-Associated Antigen-A3/A6 Is a NovelTarget of Fibroblast Growth Factor Receptor 2-IIIb through Histone H3Modifications in Thyroid Cancer (2007) (2)
- The Classification of Pituitary Tumors: An Update (2002) (1)
- ED2: COST-EFFECTIVENESS OF ACROMEGALY TREATMENTS (1999) (1)
- PANCREATIC INCIDENTALOMAS: IS IT NET OR NOT? (2016) (1)
- A minimally invasive approach to the management of bronchial carcinoid tumors associated with ectopic Cushing’s Syndrome (1998) (1)
- Growth Hormone Deficiency and Physical Function (2001) (1)
- Are Patients with Acromegaly at Increased Risk forNeoplasia{inverted question} (1991) (1)
- Lessons learned from thyroglobulin concentrations after total thyroidectomy and radioactive iodine ablation for differentiated thyroid cancer. (2015) (1)
- Growth factors and their receptors in the genesis and treatment of thyroid cancer. (2004) (1)
- AACE Acromegaly Task Force Chair (2011) (1)
- Genetics and Epigenetics of Endocrine Neoplasia (2014) (1)
- Risk of Adverse Cardiovascular Outcomes in Differentiated Thyroid Cancer Survivors: A Systematic Review and Meta-analysis. (2022) (1)
- Chromatin remodeling: the interface between extrinsic cues and the genetic code? (2008) (1)
- Pharmacological options in the treatment of acromegaly. (2005) (1)
- Book Review Thyroid Cancer Edited by H.-J. Biersack and F. Grunwald. 301 pp., illustrated. New York, Springer-Verlag, 2001. $99. 3-540-41390-1 (2001) (1)
- SCP2 variant is associated with alterations in lipid metabolism, brainstem neurodegeneration, and testicular defects (2022) (1)
- A Comprehensive Analysis of Late Toxicity, Quality Of Life and Emotional Distress In Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy At A Non-Endemic Center (2018) (1)
- ENDOCRINE COMPLICATIONS IN PATIENTS WITH GVHD. (2019) (1)
- The Diagnosis of Neuroendocrine Neoplasms (2020) (1)
- Molecular and Cellular Pathobiology FGFR 2 Isoforms Support Epithelial – Stromal Interactions in Thyroid Cancer Progression (2012) (1)
- Octreotide Treatment of Acromegaly (2020) (1)
- Hypothalamic hormone-producing tumors. (2021) (1)
- A single-arm, phase II, multicenter trial of sunitinib (SU) in locally advanced or metastatic pheochromocytoma/paraganglioma (PC/PG): Updated interim results. (2014) (1)
- A single-arm, phase II, multicenter trial of sunitinib maleate (SU) in locally advanced or metastatic pheochromocytoma/paraganglioma (PC/PG): Interim results. (2014) (1)
- Re: Quality of life and symptom impact of thyroid cancer: A cross-sectional survey of Canadian patients. (2019) (1)
- A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors (2018) (0)
- The Breast Cancer Susceptibility Gene FGFR 2 Serves as a 3 Scaffold for Regulation of NF-κβ Signaling (2012) (0)
- The Experience of Being Diagnosed with ThyroidCancer: A Qualitative Study Despite increasing numbers of patients diagnosed with well-differentiated thyroid carcinoma (WDTC), little is known about their experiences related to diagnosis (2008) (0)
- Epigenetics of Pituitary Cell Growth and Survival (2021) (0)
- Growth Hormone Treatment Improves Muscle Oxygen Extraction During Exercise in Patients with HIV-Associated Wasting (2004) (0)
- ACTH-Dependent Cushing Syndrome in Metastatic Acinic Cell Carcinoma: A Poor Prognostic Factor (2023) (0)
- PM-13IDENTIFICATION OF THERAPEUTIC TARGETS IN AN INTRACRANIAL XENOGRAFT MODEL OF PITUITARY ADENOMA (2014) (0)
- Molecular Oncology: Mechanisms of pituitary tumorigenesis (2013) (0)
- MON-325 Co-Occurrence of Breast Cancer and Neuroendocrine Tumors: More Than a Coincidence? (2019) (0)
- Prolactin, a potential biomarker for chronic GVHD activity (2020) (0)
- LBODP066 A Conservative Approach To The Management Of Glucagon Receptor (GCCR) Mutation (Mahvash Syndrome) (2022) (0)
- Hypothalamic Vasopressin-Producing Tumors (2019) (0)
- Molecular Predictors of Clinical Behavior in Pituitary Adenohypophysial Tumors (2019) (0)
- Is Hypothalamic Oxytocin Dispensable for Parturition? (2018) (0)
- upregulation of ubiquitin expression by increasing its proteasomal degradation through A chemical biology screen identifies glucocorticoids that regulate (2007) (0)
- Erratum to: Case Report: Adrenal LH/hCG Receptor Overexpression and Gene Amplification Causing Pregnancy-Induced Cushing’s Syndrome (2010) (0)
- Pituitary Endocrine Function Testing (2013) (0)
- Is autoimmune pituitary disease underdiagnosed? (2007) (0)
- Prescription and treatment patterns of lenvatinib (L) in patients with radioactive iodine-refractory differentiated thyroid cancer (rDTC): A retrospective analysis of the Canadian Patient Support Program (PSP) (2019) (0)
- SCP2 variant is associated with alterations in lipid metabolism, brainstem neurodegeneration, and testicular defects (2022) (0)
- Liver Transplantation in a Young Patient with Severe and Refractory Carcinoid Syndrome (2018) (0)
- List of contributors (2021) (0)
- The Management of Neuro-Endocrine Neoplasms (2020) (0)
- Second Primary Malignancy Risk in Thyroid Cancer Survivors Treated with Radioactive Iodine: An Updated Systematic Review and Meta-analysis (2017) (0)
- Molecular profiling confirms historical immunohistochemistry in acromegaly. (2020) (0)
- FLCN-Driven Functional Adrenal Cortical Carcinoma with High Mitotic Tumor Grade: Extending the Endocrine Manifestations of Birt-Hogg-Dubé Syndrome. (2023) (0)
- Retraction Notice to: The Cancer-Associated FGFR4-G388R Polymorphism Enhances Pancreatic Insulin Secretion and Modifies the Risk of Diabetes. (2020) (0)
- More about hyperprolactinemia (2004) (0)
- Pathology of pituitary growth hormone excess (2021) (0)
- Pituitary Tumors, Molecular Pathogenesis (2004) (0)
- Pituitary carcinoma: reclassification and implications in the NET schema (2022) (0)
- Pituitary Tumors; Diagnosis and Treatment (2018) (0)
- SUN-453 Absence of Crooke's Hyaline Changes May Predict Worse Outcomes in Patients with Cushing Disease (2019) (0)
- A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial (2019) (0)
- Endoscopic Treatment of Rathke’s Cleft Cysts: The Case for Simple Fenestration (2022) (0)
- The Pathophysiology of Pituitary Tumors (2002) (0)
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND TREATMENT OF ACROMEGALY AACE Acromegaly Guidelines Task Force Chairman (2004) (0)
- Retraction for Wei et al., “The Breast Cancer Susceptibility Gene Product Fibroblast Growth Factor Receptor 2 Serves as a Scaffold for Regulation of NF-κB Signaling” (2018) (0)
- Dispelling the Myths about Rarely Diagnosed Pituitary Disorders (2005) (0)
- Subclinical hypothyroidism. (2020) (0)
- Endocrine Gland Imaging (2019) (0)
- Thyroid Cancer Incidence and Endocrinologist Access: A Regional Data Analysis from Ontario, Canada. (2016) (0)
- A Novel Human Heterozygous SCP2 Mutation Leads to Alterations in Lipid Metabolism (2022) (0)
- Endoscopic Endonasal Surgery for Prolactinomas: Prognostic Factors for Disease Control and Management of Persistent Disease (2022) (0)
- The cancer-testis antigen MAGE-A3 is a target of FGFR2 and fibronectin signaling in thyroid cancer progression (2008) (0)
- Response: Letter to Editor "A prospective mixed-methods study of decision-making on surgery or active surveillance for low risk papillary thyroid cancer". (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Shereen Z. Ezzat?
Shereen Z. Ezzat is affiliated with the following schools:
